An analysis of the contents of the official instructions of Datopotamab

Datopotomab Deruxtecan, trade name: Datroway) is a new type of antibody- drug conjugate (ADC), jointly developed by AstraZeneca (AstraZeneca) and Daiichi Sankyo (Daiichi Jointly developed by Sankyo), it specifically targets trophoblast cell surface antigen2 (TROP2). TROP2 is a glycoprotein widely expressed on the surface of a variety of solid tumor cells. It is especially highly expressed in breast cancer, lung cancer and other cancers, and is closely related to tumor invasion and metastasis. By combining TROP2, dabrotuzumab can accurately deliver cytotoxic drugs, kill tumor cells to the maximum extent, and reduce damage to normal tissues, making it a breakthrough drug in the field of targeted therapy.

Deruxtecan has a unique structural design and is composed of a recombinant humanized anti-TROP2 IgG1 monoclonal antibody coupled with a potent topoisomerase I inhibitor (DXd). Its mechanism of action includes three steps: first, the antibody part selectively recognizes and binds to the TROP2 antigen on the surface of tumor cells; second, the drug conjugate enters the tumor cells through antibody-mediated endocytosis; finally, Deruxtecan pan>is released in cells and inhibitsDNAtopoisomeraseI, causing tumor cellDNA damage and apoptosis. This precise delivery system not only improves the anti-tumor effect, but also significantly reduces systemic toxic side effects and improves patient tolerance and quality of life.

Clinically, dabrotuzumab has performed well in a number of key clinical trials. TROPION-Breast01 is one of its most important III registration trials. The study included 732 patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had received endocrine therapy and chemotherapy. The trial results showed that the median progression-free survival of patients using dedabrotuzumab reached 6.9 months, and the disease control rate was as high as 67%, significantly better than the traditional chemotherapy group. In addition, dabrotuzumab is also being studied in clinical trials of multiple solid tumor types such as non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), showing broad application potential.

However, the use of dabrotuzumab is also associated with certain side effects. Common adverse reactions include stomatitis, nausea, fatigue, alopecia, anemia, leukopenia, dry eyes and keratitis. Due to the cytotoxic properties of Deruxtecan, some patients may experience abnormal liver function, such as elevated levels of AST and ALT. For this reason, it is necessary to closely monitor the patient's blood routine and liver function during clinical medication, deal with adverse reactions in a timely manner, and adjust the dosage or suspend treatment when necessary. Doctors will develop personalized management plans based on the patient's specific conditions to ensure safe and effective treatment.

The launch of dabrotuzumab brings new therapeutic hope to patients with advanced breast cancer and otherTROP2 positive solid tumors. As one of the first anti-TROP2 ADC drugs to be approved by the FDA, its successful launch not only enriches the targeted treatment methods, but also provides a solid guarantee for cancer patients to extend their survival and improve their quality of life. With the subsequent expansion of more indications and the accumulation of more clinical data, dabrotuzumab is expected to become an important pillar in the field of tumor treatment.

In summary, dedabrotuzumab combines efficient targeting, precise drug delivery and good tolerability, and represents the cutting-edge progress of antibody- drug conjugation technology. When receiving treatment, patients should follow medical advice, regularly review and monitor side effects to ensure medication safety. At the same time, medical institutions and scientific research teams are constantly working hard to promote its application in more tumor types and optimize dosage regimens, hoping to benefit more patients and push the anti-cancer cause to a new peak.

Reference materials:https://www.drugs.com/